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Purpose: Current pharmacotherapy for persistent pain related to neuropathy or articular 
diseases is unsatisfactory, due to the large number of unresponsive patients and side effects. 
Isothiocyanates (ITCs) are a class of natural or synthetic compounds characterized by the general 
formula R–NCS. ITCs show antihyperalgesic effects in models of central and peripheral nervous 
tissue injury and anti-inflammatory properties. The pharmacodynamics are strictly related to the 
release of the gasotransmitter hydrogen sulfide (H
2
S) from their moiety. In particular, phenyl 
ITC (PITC) and 3-carboxyphenyl ITC (3C-PITC) exhibit interesting slow H
2
S-release properties 
suitable for treating painful pathology. The aim of the present work was to evaluate the efficacy 
of PITC and 3C-PITC against mechanical hyperalgesia and spontaneous pain induced by nerve 
injury and osteoarthritis.
Methods: Nerve injury and osteoarthritis were induced in rats by ligation of the sciatic nerve 
(chronic constriction injury) and intra-articular injection of monoiodoacetate, respectively. 
Behavioral tests were performed 14 days after damage induction.
Results: Single subcutaneous administrations of PITC, 3C-PITC (4.43 and 13.31 µmol kg-1, 
respectively) were able to completely reverse hypersensitivity to noxious stimuli in both models 
of neuropathic and osteoarticular pain. The effect of ITCs was compared with that of NaHS, 
the prototypical H
2
S donor, showing similar efficacy and higher potency. ITCs and NaHS also 
reduced spontaneous pain.
Conclusion: ITCs offer a promising novel approach to counteract persistent, drug-resistant 
painful pathology.
Keywords: neuropathic pain, nerve injury, osteoarthritis, isothiocyanate, H
2
S
Introduction
Persistent pain is a grave and debilitating condition that affects approximately a quar-
ter of the population and is often associated with a considerable reduction in quality 
of life.1 There are many forms of persistent pain. Neuropathy- and arthritis-related 
pain are among the prevalent causes.2,3 Neuropathy results from central or peripheral 
nervous system damages.4 Pharmacological therapy for neuropathic pain still shows 
limited efficacy, combined with several side effects that limit increases in dosage.5 
Osteoarthritis is a multifactorial joint disease, and includes joint degeneration, inter-
mittent inflammation, and peripheral neuropathy, so it is characterized by persistent 
pain with both inflammatory and neuropathic components.6,7 The joint erosion also 
impairs local sensory afferents, leading to sensitization of the peripheral nervous system 
which may result in central augmentation of nociceptive processing.7 As consequence 
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of severe osteoarthritis, an increasing number of patients 
exhibit neuropathic pain-like symptoms.6 In osteoarthritic 
patients, anti-inflammatory drugs are the first choice in the 
treatment of pain, despite their limited efficacy and several 
side effects, particularly in the elderly.8 The development 
of novel therapeutics for an effective and safe treatment 
of these types of pain becomes necessary. Isothiocyanates 
(ITCs) are a class of natural or synthetic compounds with 
the general formula R–NCS.9 Natural ITCs derive from the 
hydrolysis of glucosinolates, secondary metabolites mainly 
present in plants belonging to the family of Brassicaceae.10 
Glucosinolates and ITCs show beneficial effects in models 
of central and peripheral nervous tissue injury, as well as in 
carcinogenesis and cardiovascular diseases.11–16 Moreover, 
ITCs exhibit anti-inflammatory properties as they act on 
the regulation of NFkB, the modulation of TNFa, and the 
lipopolysaccharide-stimulated inflammatory response.17–20 
Recently, we demonstrated the efficacy of subcutaneous (SC) 
and intracerebroventricular administration of different ITCs 
in a mouse model of chemotherapy-induced neuropathic 
pain.21 According to previously reported in vivo data,21 we 
found that the pharmacodynamics were closely related to the 
release of the gasotransmitter H
2
S.16 Among all natural and 
synthetic ITCs, phenyl ITC (PITC) and 3-carboxyphenyl ITC 
(3C-PITC) are endowed with interesting slow H
2
S-release 
properties that make them suitable for pharmacological 
applications.16,22 Indeed, PITC and 3C-PITC possess an 
optimal efficacy/potency profile in relieving chemotherapy-
induced neuropathic pain.21 The aim of the present work was 
to evaluate the efficacy of PITC and 3C-PITC in reducing 
mechanical hyperalgesia and spontaneous pain in two rat 
models of persistent pain: traumatic injury to the sciatic 
nerve (chronic constriction injury [CCI]) and chemical ero-
sion of the tibiotarsal joint (monoiodoacetate [MIA]).23,24 The 
efficacy of ITCs was also compared with the prototypical 
H
2
S donor NaHS.25
Methods
Animals
Male Sprague Dawley rats (Envigo, Huntingdon, UK) weigh-
ing approximately 200–250 g were employed. Animals were 
housed in the Centro Stabulazione Animali da Laboratorio, 
University of Florence and used at least 1 week after their 
arrival. Four rats were housed per cage (26×41 cm) kept at 
23°C±1°C with a 12-hour light–dark cycle (light at 7 am), and 
were fed a standard laboratory diet and tap water ad libitum. 
All animal manipulations were carried out according to direc-
tive 2010/63/EU of the European Parliament and European 
Union Council (September 22, 2010) on the protection of 
animals used for scientific purposes. The ethical policy of the 
University of Florence complies with the Guide for the Care 
and Use of Laboratory Animals of the US National Institutes 
of Health (NIH publication 85-23, revised 1996; University 
of Florence assurance number A5278-01). Formal approval 
to conduct the experiments described was obtained from the 
Animal Subjects Review Board of the University of Florence. 
Experiments involving animals have been reported according 
to ARRIVE (animal research: reporting in vivo experiments) 
guidelines.26 All efforts were made to minimize animal suf-
fering and the number of animals used.
CCI-induced neuropathic pain model
Neuropathy was induced according to the procedure 
described by Bennett and Xie.23 Briefly, rats were anesthetized 
with 2% isoflurane. Under aseptic conditions, the right (ipsi-
lateral) common sciatic nerve was exposed at the level of the 
middle thigh by blunt dissection. Proximal to the trifurcation, 
the nerve was freed carefully from the surrounding connec-
tive tissue, and four chromic cat-gut ligatures (4-0; Ethicon, 
Somerville, NJ, USA) were tied loosely around the nerve with 
about 1 mm spacing between ligatures. After hemostasis had 
been confirmed, the incision was closed in layers. Animals 
were allowed to recover from surgery and then housed one 
per cage with free access to water and standard laboratory 
chow. Control rats were subjected to sham surgery in which 
the sciatic nerve was only exposed, but not ligated. Behav-
ioral measurements were performed on day 14 after ligation.
MIA-induced osteoarthritis model
Unilateral osteoarthritis was also induced by injection of MIA 
(Sigma-Aldrich, St Louis, MO, USA) into the knee joint.24 On 
day 1, rats were anesthetized slightly with 2% isoflurane, fol-
lowing abolition of the hind-paw pinch-withdrawal reflex, a 
27-gauge needle was introduced into the joint cavity between 
the tibial plateau and femoral condyles. MIA (2 mg) in 25 
µL saline was delivered into the left articular cavity. Control 
rats were treated with an equal volume of saline. Behavioral 
measurements were performed on day 14.
Compound administrations
PITC (Sigma-Aldrich) and 3C-PITC (Fluorochem, Hadfield, 
UK) were dissolved in saline solution with 0.5% polyethylene 
glycol. Sodium hydrosulfide hydrate (NaHS; Sigma-Aldrich) 
was dissolved in saline solution. Acute measures were per-
formed after SC administration of 4.43 and 13.31 µmol kg–1 
PITC, 3C-PITC, and NaHS.
Journal of Pain Research 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2907
Isothiocyanate efficacy for persistent pain
Paw-pressure test
The nociceptive threshold in each rat was determined with 
an analgesimeter (Ugo Basile, Gemonio, Italy) according 
to the method described by Leighton et al.27 Briefly, a con-
stantly increasing pressure was applied to a small area of the 
dorsal surface of the paw using a blunt conical probe with a 
mechanical device. Mechanical pressure was increased until a 
withdrawal reflex occurred while rats were lightly restrained. 
Vocalization or withdrawal-reflex thresholds are expressed 
in grams. Rats scoring <40 g or >80 g during the test before 
drug administration were rejected (25%).
Incapacitance test
Weight-bearing changes were measured using an inca-
pacitance apparatus (Linton Instrumentation, Diss, UK) 
detecting changes in postural equilibrium after a hind-limb 
injury.28 Rats were trained to stand on their hind paws in a 
box with an inclined plane (65° from horizontal). This box 
was placed above the incapacitance apparatus. This allowed 
us independently to measure the weight that the animal 
applied on each hind limb. The value considered for each 
animal was the mean of five consecutive measurements. 
In the absence of hind-limb injury, rats applied an equal 
weight on both hind limbs, indicating postural equilibrium, 
whereas an unequal distribution of the weight on hind limbs 
indicated a monolaterally decreased pain threshold. Data are 
expressed as the difference between the weight applied on 
the limb contralateral to the injury and the weight applied 
on the ipsilateral one (Δweight).
Statistical analysis
Behavioral measurements were performed on ten rats for 
each treatment carried out in two different experimental sets. 
All experimental procedures were performed by a researcher 
blind to the treatment. Standard ANOVA followed by Fisher’s 
protected least significant difference procedure were used. 
Results are expressed as mean ± standard error of the mean 
(SEM). All assessments were made by researchers blinded to 
rat treatments. Data were analyzed using Origin 9.1 (Origin-
Lab, Northampton, MA, USA).
Results
Animals with monolateral peripheral neuropathy show an 
amplified response to mechanical stimuli on the ipsilateral paw 
and postural balance impairments related to the presence of 
ongoing pain. On day 14 after right sciatic nerve ligation, the 
weight tolerated on the ipsilateral paw was significantly lower 
(43.3±3.3 g, CCI + vehicle) in respect of sham-operated animals 
(68.3±3.1 g, sham + vehicle; Figure 1A). The effects of a single 
SC administration of two different doses of PITC, 3C-PITC 
and NaHS on CCI-induced mechanical hypersensitivity (mea-
sured by paw-pressure test) are shown in Figure 1. Both doses 
of PITC completely abolished mechanical  hypersensitivity in 
Figure 1 Effects of PITC, 3C-PITC, and NaHS on chronic constriction injury (CCI)-
induced mechanical hypersensitivity.
Notes: Mononeuropathy was induced by ligation of the right sciatic nerve (CCI). 
Control animals were sham-operated and treated with vehicles. Mechanical 
hypersensitivity was evaluated by paw-pressure test, and data are expressed as the 
weight (g) that the animal tolerated on the paw. On day 14 after surgery, PITC (A), 
3C-PITC (B), and NaHS (C) were each administered subcutaneously at doses of 
4.43 and 13.31 μmol kg–1 and measurements assessed before and 15, 30, 45, 60 and 
90 minutes after injection. Each value represents the mean of ten rats per group, 
performed in two different experimental sets. ^^P<0.01 vs controls (sham + vehicle-
treated rats); *P<0.05, **P<0.01 vs CCI + vehicle-treated rats.
Abbreviations: PITC, phenyl ITC; 3C-PITC, 3-carboxyphenyl ITC.
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CCI animals between 15 and 30 minutes after administration, 
and the effect of 13.31 µmol kg–1 PITC lasted until 45 minutes 
(Figure 1A). Both doses of 3C-PITC were active between 15 
and 45 minutes: 4.43 µmol kg–1 3C-PITC peaked at 30 minutes, 
while the effect of the higher dose plateaued from 15 minutes 
and lasted up to 45 minutes (Figure 1B). The effect of NaHS 
was dose-dependent, with a maximum at 15 minutes after 
administration for both doses (Figure 1C).
In Figure 2, the acute effects of two different doses 
of PITC, 3C-PITC and NaHS on CCI-induced hind-limb 
weight-bearing alterations (measured by incapacitance 
test) are shown. On day 14 after operation, the difference 
between the weight burden on the contralateral and ipsilat-
eral limbs (Δweight) was significantly increased in CCI + 
vehicle (61.9±1.3 g) with respect to sham + vehicle (5.3±1.2 
g,  Figure 2). Both doses of PITC significantly decreased 
Δweight (~50%) between 15 and 30 minutes after admin-
istration. The effect of 4.43 µmol kg–1 PITC lasted longer, 
being significant even at 60 minutes (Figure 2A). Following 
the administration of both doses of 3C-PITC, CCI-induced 
postural imbalance was reduced by ~60% (Figure 2B). The 
lower dose was active between 15 and 45 minutes, while the 
effect of the higher dose began 30 minutes after administra-
tion. Both doses of NaHS reduced Δweight by ~50%. The 
effect of 4.43 µmol kg–1 NaHS was maximal between 30 and 
45 minutes, whereas the effect of the higher dose showed a 
peak 15 minutes after administration (Figure 2C).
The pharmacological activity of PITC, 3C-PITC, and 
NaHS (SC administration) was also evaluated in the rat 
unilateral osteoarthritis model induced by MIA. On day 
14 after intra-articular MIA injection, the weight toler-
ated by the animals on the ipsilateral paw was significantly 
reduced (42.5±3.5 g) compared to control rats (73.2±2.4 g; 
 Figure 3A). PITC (13.31 µmol kg–1) significantly increased 
pain threshold between 15 and 45 minutes after administra-
tion, while the lower dose was less effective and delayed over 
time (Figure 3A). The effect of 3C-PITC was dose-dependent: 
both dosages produced a maximum effect 15 minutes after 
administration that lasted until 45 minutes (Figure 3B). The 
higher dose of 3C-PITC reverted mechanical hypersensitivity 
induced by MIA injection. Both doses of NaHS were active 
between 15 and 45 minutes (60±5.7 g and 56.6±0.8 g for 4.43 
and 13.31 µmol kg–1, respectively; Figure 3C).
In Figure 4, the effects of PITC, 3C-PITC, and NaHS 
on MIA-induced hind-limb weight-bearing alterations are 
shown. On day 14 after intra-articular MIA injection, Δweight 
was significantly increased in MIA + vehicle (64.5±3.6 g) 
with respect to vehicle + vehicle (10.4±1.3 g; Figure 4A). 
Both doses of PITC and 3C-PITC were equally active, 
decreasing Δweight by ~50% between 15 and 45 minutes 
( Figure 4A and B). Both doses of NaHS were able to reduce 
Δweight by ~50%: the lower dose was active between 30 and 
45 minutes and the higher dose between 15 and 30 minutes 
(Figure 4C).
Discussion
From the present results, the preclinical efficacy of acute 
administration of ITCs or NaHS against neuropathic and 
osteoarthritic pain was proven. PITC and 3C-PITC were able 
to completely revert alterations in pain thresholds induced by 
CCI nerve surgery and MIA intra-articular injection. Neu-
ropathic pain manifestations include spontaneous (tingling, 
burning, electric shock-like) pain, dysesthesia, paresthesia, 
allodynia (pain resulting from normally unpainful stimuli), 
and hyperalgesia (an increased response to painful stimuli).29 
Its impact on people’s health is strong, leading to the loss of 
work ability and becoming a social and economic burdens.30 
Current pharmacological treatments for neuropathic pain, 
which include tricyclic antidepressants, serotonin-reuptake 
inhibitors, anticonvulsants, and opioids, have limited efficacy 
and a considerable number of side effects.5 The animal model 
of nerve CCI developed by Bennett and Xie reproduces 
many features of neuropathic pain disorders that occur in 
humans.23,31 Animals show altered spontaneous behavior 
consistent with the presence of ongoing neuropathic pain, 
lowered thresholds, and exaggerated responses to thermal 
and mechanical stimuli.32,33 Therefore, this model can be 
effectively used to study the efficacy of novel treatments for 
neuropathic pain.
Osteoarthritis is likewise characterized by persistent pain 
with inflammatory and neuropathic components, whose most 
common symptoms are stiffness and increasing pain at rest 
and in the chronic phase hyperalgesia.6,7,31 In particular, this 
pathology is characterized by a progressive loss of articular 
cartilage, new bone formation, and synovial proliferation, 
which result in inflammation, loss of joint function, and pain. 
The progressive damage of peripheral nerve ends evokes a 
neuropathic component that contributes to pain chronic-
ity.6,34,35 The injection of MIA into the intra-articular space of 
the knee is an established and well-characterized preclinical 
model of osteoarthritis consistent with human pathophysiol-
ogy and clinical symptoms.34,36,37
Both CCI- and MIA-induced pain models present an 
initial relevant inflammatory condition that gradually 
evolves in neuropathic aspects.35,38 Since the therapies 
currently in use for neuropathic and osteoarthritic pain 
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Figure 2 Effects of PITC, 3C-PITC, and NaHS on chronic constriction injury (CCI)-induced postural imbalance.
Notes: Mononeuropathy was induced by ligation of the right sciatic nerve (CCI). Control animals were sham-operated and treated with vehicles. Weight-bearing changes 
were evaluated by incapacitance test and data are expressed as the difference (Δweight) between the weight applied on the limb contralateral to the injury and the weight 
applied on the ipsilateral one. On day 14 after animal operation, PITC (A), 3C-PITC (B), and NaHS (C) were each administered subcutaneously at doses of 4.43 and 13.31 
μmol kg–1 and measurements assessed before treatment and 15, 30, 45, 60 and 90 minutes after injection. Each value represents the mean of ten rats per group, performed 
in two different experimental sets. ^^P<0.01 vs sham + vehicle-treated animals; *P<0.05, **P<0.01 with respect to the pretest.
Abbreviations: PITC, phenyl isothiocyanate; 3C-PITC, 3-carboxyphenyl ITC.
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Figure 3 Effects of PITC, 3C-PITC, and NaHS on monoiodoacetate (MIA)-induced mechanical hypersensitivity.
Notes: Monoarthritis was induced by injection of MIA (2 mg/25 μL saline solution) in the right (ipsilateral) articular cavity. The left (contralateral) joint was injected with 
the same volume of saline. Mechanical hypersensitivity was evaluated by paw-pressure test and data expressed as the weight (g) that the animal tolerated on the paw. On 
day 14, PITC (A), 3C-PITC (B), and NaHS (C) were each administered subcutaneously at doses of 4.43 and 13.31 μmol kg–1 and measurements assessed before treatment 
and 15, 30, 45, 60 and 90 minutes after injection. Each value represents the mean of ten rats per group, performed in two different experimental sets. ^^P<0.01 vs vehicle + 
vehicle-treated animals; *P<0.05, **P<0.01 vs MIA + vehicle-treated rats.
Abbreviations: PITC, phenyl isothiocyanate; 3C-PITC, 3-carboxyphenyl ITC.
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have so far been unsatisfactory, the good activity and high 
potency presently shown by ITCs is noteworthy. PITC and 
3C-PITC are H
2
S-releasing compounds, and the involve-
ment of this gasotransmitter in their antinociceptive effects 
has already been demonstrated.16,21,22 The prototypical H
2
S 
donor NaHS showed similar efficacy to ITCs, despite being 
less potent, probably because of the faster H
2
S-release 
kinetic. ITCs and NaHS also reduce postural imbalance, a 
feature of neuropathy progression that occurs in both mod-
els of mono-lateral neuropathy.23,28 This measure assesses 
the somatosensory component, highlighting spontaneous, 
unevoked pain.7
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Figure 4 Effects of PITC, 3C-PITC, and NaHS on monoiodoacetate (MIA)-induced postural imbalance.
Notes: Monoarthritis was induced by injection of MIA (2 mg/25 μL saline solution) in the right (ipsilateral) articular cavity. The left (contralateral) joint was injected with the 
same volume of saline. Weight-bearing changes were evaluated by incapacitance test and data expressed as the difference (Δweight) between the weight applied on the limb 
contralateral to the injury and the weight applied on the ipsilateral one. On day 14, PITC (A), 3-C-PITC (B), and NaHS (C) were each administered subcutaneously at doses 
of 4.43 and 13.31 μmol kg–1 and measurements assessed before treatment and 15, 30, 45, 60 and 90 minutes after injection. Each value represents the mean of ten rats per 
group, performed in two different experimental sets. ^^P<0.01 vs vehicle + vehicle-treated animals; **P<0.01 with respect to the pretest.
Abbreviations: PITC, phenyl isothiocyanate; 3C-PITC, 3-carboxyphenyl ITC.
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In accordance with our results, several studies have sug-
gested significant pain-relieving effects of NaHS and other 
H
2
S donors against neuropathic and visceral pain.39–41 On the 
other hand, the beneficial effects of ITCs in models of central 
and peripheral nervous tissue injury and their efficacy in 
inflammatory states have been shown.11–14 In particular, their 
anti-inflammatory properties were assigned to the regulation 
of NFkB, modulation of TNFa, and lipopolysaccharide-
stimulated inflammatory response.17–20
It is important to note that PITC, 3C-PITC, and NaHS show 
pain-relieving efficacy after acute systemic administration of 
very low doses. Furthermore, these compounds reach their 
maximum effect very quickly. This last property could be very 
useful in the treatment of acute pain attacks in patients with 
chronic pain conditions. Furthermore, their anti-inflammatory 
and antioxidative properties could offer further advantages in 
reducing disease progression by repeated treatments.
As a whole, the results gathered encourage us to continue 
to investigate the efficacy of these compounds in pain therapy. 
In particular, our efforts will be oriented to improve the phar-
macokinetic profile of these compounds to make their effect 
longer-lasting. On the other hand, our recent in vivo data 
demonstrating that the antinociceptive effects of ITC-based 
compounds are mediated by their capacity of H
2
S release,21 
suggest that more persistent effects could be obtained by the 
modulation of H
2
S release from ITCs or by the identification 
of ITCs with a slow H
2
S-release profile. In fact, the effects 
displayed by this gasotransmitter show rapid kinetics, both in 
vivo and in vitro: H
2
S is able to reach the bloodstream easily 
and then its molecular targets on the cell membrane, inside the 
cytosol, or in intracellular organelles.42 From this perspective, 
the increase in ITC-effect duration would also be achieved by 
the application of sustained-release dosage forms.
Conclusion
Overall, this evidence, along with the data reporting the 
effectiveness of ITCs also in chemotherapy-induced neuro-
pathic pain, can lead to a new and innovative strategy to treat 
traditional drug-resistant forms of pain, particularly in view 
of ITCs effectiveness and potency.21
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